A869 0,9% saline on the costs of IV fluids and costs associated with fluid-related complications. The target population was adult patients (age ≥ 18 years) meeting SIRS criteria and receiving solely crystalloid IV fluids. The interventions compared were: patients mainly receiving BAL fluid mix versus patients receiving IV fluid therapy without BAL fluid mix considering an increasing adoption rate over 5-year period. Results: The base case was defined as a 300-bed hospital with 90% occupancy, a 2.7% SIRS frequency among inpatients, current BAL adoption level of 2%, projected year 5 BAL adoption levels of 20%. The patient number per month requiring fluid resuscitation calculated was 47 (564 per year). The overall savings were calculated by subtracting the costs of complications and treatments associated with BAL adoption level for a given year from costs associated with current BAL adoption level and adding the incremental costs.
Acupuncture use was nearly six times more common among chiropractic users than in the overall population (2.2% vs. 0.37%); similarly, nearly half (42.5%) of acupuncture users also had a claim for chiropractic. Over one-in-five patients (21.0%) with general joint or back pain used chiropractic, of which 2.65% also used acupuncture. CONCLUSIONS: Despite trends suggesting increased use of chiropractic and acupuncture, their use remains very low in commercial health insurance plans, including patients with inflammation and pain-related conditions. While still very low, acupuncture use was more common among chiropractic users than in the overall population.
The addition of IVIG to standard treatment in the treatment of childhood ITP with life threatening bleeding is a cost-effective intervention in Thailand. This evidence supported the decision-making that IVIG should be included in the health-benefit package as the first-line therapy of childhood ITP with life threatening bleeding.
Kong SLE patients compared to standard care. METHODS: A lifetime microsimulation model was adapted with epidemiological and cost data from Hong Kong. The model compares the use of belimumab against standard care and incorporates the BLISS-52 and BLISS-76 trial data for the short term outcomes within one year, while long-term outcomes were based on a natural history model developed using the Johns Hopkins Lupus registry. The natural history model describes the relationship between disease activity and other covariates on the risk of dying and developing organ damage. Data available from the SLE population in Hong Kong was used as input in the modified model. The analysis was performed from a Hong Kong health-care perspective. In the base case, cost and effectiveness were discounted to the year of analysis at 5% p.a. RESULTS: The base case analysis showed that compared to standard care, treatment with belimumab increased life expectancy by 0.80 (2.77 undiscounted) and QALY by 0.60 (1.68 undiscounted) years respectively.
retreatment regimens, which allows continuous or paused therapeutic schemes. This study aims to perform cost-effectiveness and cost-utility analyses of biologic alternatives for moderate to severe psoriasis in Venezuela, from a public payer=s perspective. METHODS: A decision-tree model simulates psoriasis evolution after treatment with etanercept continuous (50mg twice a week for 12 weeks, followed by 25mg twice a week) or paused (12-week treatment cycle and 12-week interruption), adalimumab (80mg at first week, followed by 40mg in the second week, then 40mg every 2 weeks), infliximab (5 mg/kg at weeks 0, 2 and 6, then every 8 weeks) or ustekinumab (45mg in weeks 0 and 4, then 45mg every 12 weeks) and their associated costs in a 96-week time horizon. Therapy continuation or switch was evaluated at week 24. Effectiveness measures were PASI 75 success rate and quality adjusted life years (QALY) gained. Costs included biologicals, medical follow-up and adverse events management, from Venezuela official databases (values represented 2010 USD). Probabilistic sensitivity analyses were performed through Monte Carlo simulation. A 5% discount rate was applied for costs and benefits. RESULTS: Effectiveness resulted in [
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.